期刊文献+

不同剂量孕激素治疗无排卵型月经失调对比分析 被引量:7

Comparative Analysis of Different Doses of Progesterone for Menstrual Disorder of Anovulatory Group
下载PDF
导出
摘要 目的分析不同剂量孕激素在治疗无排卵型月经失调中的疗效。方法选取2014年8月~2015年2月我院收治符合无排卵型月经失调诊断标准的患者80例,将所有患者随机分为A、B、C、D 4组,给予A组100 mg、B组200 mg、C组300 mg、D组400 mg口服黄体酮治疗,分析比较4组治疗效果。结果对4组治疗疗效对比中,4组治疗疗效差异无统计学意义(P〉0.05);在不良反应对比中,A组不良反应低于其他3组,差异具有统计学意义(P〈0.05);经过治疗后,4组患者出血量均得到有效的控制,组间差异无统计学意义(P〉0.05)。结论不同剂量的孕激素在治疗无排卵型月经失调中均取得良好的治疗效果,考虑药物使用剂量安全性应给予患者最低剂量的孕激素,以达到安全、高效的临床效果。 Objective To analyze the treatment effect of menstrual disorder treated by different dose of progestational hormone. Methods To selected 80 cases of patients conformed to the standard of menstrual disorder at our hospital from August 2014 to February 2015,to randomly divided into the group A, B,C and D that 4 groups. The group A was given 100 mg, group B was 200 mg,the group C was 300 mg and the group D was 400 mg of the progesterone. To analyzebthe treatment effect. Results To compared the treatment effect,there was no statistical significance(P〈0.05). To compared the adverse reactions,the group A was lower than the other three groups,there was statistical significance(P〈0.05). After treatment,the amount of bleeding was controlled of them,there was no statistical significance(P〈0.05). Conclusion That all has the favourable treatment effect of the different dose of progesterone for the menstrual disorder of anovulatory group,there should to given the lowest dose level of progestational hormone that considered the safety of using dose,so that to reach the clinic effect of safety and efficient.
作者 陈利华
出处 《中国卫生标准管理》 2016年第6期112-114,共3页 China Health Standard Management
关键词 孕激素 不同剂量 无排卵型月经失调 Progestational hormone Different dose Menstrual disorder of anovulatory group
  • 相关文献

参考文献3

二级参考文献47

  • 1陈洁,王梅琴.致康胶囊治疗宫内节育器导致的月经失调观察[J].浙江中医药大学学报,2010,34(4):556-556. 被引量:4
  • 2陈正琼,成娅.胎盘激素与妊娠期糖尿病[J].重庆医学,2005,34(1):58-60. 被引量:4
  • 3陈正琼,成娅,陈浩波,林桂兰.妊娠期糖耐量异常患者血清E2、P、PRL水平变化及其与瘦素水平的关系[J].重庆医学,2006,35(6):528-529. 被引量:8
  • 4沈春芳,洪洁,张翼飞,顾卫琼,王卫庆,李小英,王敏敏,喇端端,侍庆,宁光.妊娠糖尿病患者胰岛素抵抗与血清C反应蛋白水平的相关性研究[J].内科理论与实践,2008,3(1):37-40. 被引量:13
  • 5Szekeres-Bartho J, Wilczynski JR, Basta P, et al. Role of progesterone and progestin therapy in threatened abortion and preterm labour[J]. Front Biosei, 2008, 13: 1981-1990.
  • 6Bender NM, Segall-Gutierrez P, Najera SO, et al. Effects of progestin-only long-acting contraception on metabolic markers in obese women[J]. Contraception, 2013, 88(3): 418-425.
  • 7American Diabetes Association. Standards of medical care in diabetes--2012[J]. Diabetes Care, 2012, 35 Suppl 1: S 11-63.
  • 8Hedderson MM, Ferrara A, Williams MA, et al. Androgenicity of progestins in hormonal contraceptives and the risk of gestational diabetes mellitus[J]. Diabetes Care, 2007, 30(5): 1062-1068.
  • 9Xiang AH, Kjos SL, Takayanagi M, et al. Detailed physiological characterization of the development of type 2 diabetes in Hispanic women with prior gestational diabetes mellitus[J]. Diabetes, 2010, 59(10): 2625-2630.
  • 10Wolfe K, Dearmond C, How H, et al. The rates of abnormal glucose challenge tests and gestational diabetes in women receiving 17alpha-hydroxyprogesterone caproate[J]. Am J Perinatol, 2011, 28(10): 741-746.

共引文献38

同被引文献27

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部